{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:22:32Z","timestamp":1792790552366,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008558","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000}}],"reference-count":262,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008558.pub2","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T16:58:37Z","timestamp":1575392317000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus"],"prefix":"10.1002","volume":"2019","author":[{"given":"Kasper S","family":"Madsen","sequence":"first","affiliation":[{"name":"University of Copenhagen; Faculty of Health and Medical Sciences; Blegdamsvej 3B Copenhagen N Denmark 2200"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chi","sequence":"additional","affiliation":[{"name":"University Hospital Zurich and University of Zurich; Institute for Complementary and Integrative Medicine; Sonneggstrasse 6 Zurich Beijing Switzerland 8006"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Inti","family":"Metzendorf","sequence":"additional","affiliation":[{"name":"Institute of General Practice, Medical Faculty of the Heinrich-Heine-University D\u00fcsseldorf; Cochrane Metabolic and Endocrine Disorders Group; Moorenstr. 5 D\u00fcsseldorf Germany 40225"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Richter","sequence":"additional","affiliation":[{"name":"Institute of General Practice, Medical Faculty of the Heinrich-Heine-University D\u00fcsseldorf; Cochrane Metabolic and Endocrine Disorders Group; Moorenstr. 5 D\u00fcsseldorf Germany 40225"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Hemmingsen","sequence":"additional","affiliation":[{"name":"Institute of General Practice, Medical Faculty of the Heinrich-Heine-University D\u00fcsseldorf; Cochrane Metabolic and Endocrine Disorders Group; Moorenstr. 5 D\u00fcsseldorf Germany 40225"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,12,3]]},"reference":[{"key":"10.1002\/14651858.CD008558.pub2-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Alfawaz HA Wani K Alnaami AM Al-Saleh Y Aljohani NJ Al-Attas OS Effects of different dietary and lifestyle modification therapies on metabolic syndrome in prediabetic Arab patients: a 12-month longitudinal study Nutrients 2018 pii: E383","DOI":"10.3390\/nu10030383"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Charles MA Morange P Eschwege E Andre P Vague P Juhan-Vague I Effect of weight change and metformin on fibrinolysis and the von willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the prevention of the risk of obesity Diabetes Care 1998","DOI":"10.2337\/diacare.21.11.1967"},{"issue":"1 Pt 2","key":"10.1002\/14651858.CD008558.pub2-BIB0003|cit3","first-page":"249","article-title":"BIGPRO (biguanides and the prevention of the risk of obesity): study design. A randomized trial of metformin versus placebo in the correction of the metabolic abnormalities associated with insulin resistance","volume":"17","author":"Fontbonne","year":"1991","journal-title":"Diabetes & Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD008558.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.diabet.2009.03.005","article-title":"Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial","volume":"35","author":"Fontbonne","year":"2009","journal-title":"Diabetes & Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD008558.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/diacare.19.9.920","article-title":"The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution","volume":"19","author":"Fontbonne","year":"1996","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD008558.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3969\/j.issn.1005-7072.2009.01.026","article-title":"Intervene effect of Shenqi Jiangtang Capsule on type 2 diabetes developed from low glucose tolerance","volume":"16","author":"Chen","year":"2009","journal-title":"Chinese Journal of Traditional Medical Science and Technology [\u4e2d\u56fd\u4e2d\u533b\u836f\u79d1\u6280]"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0019|cit7","unstructured":"Diabetes Prevention Program Outcomes Study (DPPOS) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00038727"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0007|cit8","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1210\/jc.2014-3761","article-title":"The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up","volume":"100","author":"Aroda","year":"2015","journal-title":"Journal Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0008|cit9","doi-asserted-by":"crossref","unstructured":"Aroda VR Edelstein SL Goldberg RB Knowler WC Marcovina SM Orchard TJ Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study Journal of Clinical Endocrinoligy & Metabolism 2016 1754 61","DOI":"10.1210\/jc.2015-3754"},{"issue":"9","key":"10.1002\/14651858.CD008558.pub2-BIB0009|cit10","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00125-017-4361-9","article-title":"Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program\/Diabetes Prevention Program Outcomes Study","volume":"60","author":"Aroda","year":"2017","journal-title":"Diabetologia"},{"issue":"6","key":"10.1002\/14651858.CD008558.pub2-BIB0010|cit11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.japh.2017.05.015","article-title":"The changing cost to prevent diabetes: a retrospective analysis of the Diabetes Prevention Program","volume":"57","author":"Carris","year":"2017","journal-title":"Journal of the American Pharmaceutical Association"},{"issue":"10","key":"10.1002\/14651858.CD008558.pub2-BIB0011|cit12","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/gerona\/61.10.1075","article-title":"The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes","volume":"61","author":"Crandall","year":"2006","journal-title":"The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences"},{"issue":"1","key":"10.1002\/14651858.CD008558.pub2-BIB0012|cit13","doi-asserted-by":"crossref","first-page":"e000438.","DOI":"10.1136\/bmjdrc-2017-000438","article-title":"Statin use and risk of developing diabetes: results from the Diabetes Prevention Program","volume":"5","author":"Crandall","year":"2017","journal-title":"BMJ Open Diabetes Research and Care"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0013|cit14","doi-asserted-by":"crossref","first-page":"A408","DOI":"10.2337\/db18-1523-P","article-title":"Using mets severity to track risk for type 2 diabetes during intervention with lifestyle and metformin","volume":"67","author":"Deboer","year":"2018","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0014|cit15","unstructured":"Diabetes Prevention Program (DPP) Group Protocol for the Diabetes Prevention Program (DPP) https:\/\/dppos.bsc.gwu.edu\/documents\/1124073\/1127212\/DPPPROTOCOL.PDF\/807eddd1-d9bf-497d-89f0-5de15fc43d79"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0015|cit16","unstructured":"Diabetes Prevention Program (DPP) Group Protocol for the Diabetes prevention Program Outcomes Study (DPPOS) https:\/\/dppos.bsc.gwu.edu\/documents\/1124073\/1127212\/Version+4.2+May+1%2C+2016\/14e782f2-2da9-47d1-a501-6004bcaee74e"},{"issue":"12","key":"10.1002\/14651858.CD008558.pub2-BIB0016|cit17","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.2337\/diacare.25.12.2165","article-title":"The Diabetes Prevention Program (DPP): description of lifestyle intervention","volume":"25","author":"Diabetes Prevention Program (DPP) Research Group","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0017|cit18","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2337\/diacare.23.11.1619","article-title":"The Diabetes Prevention Program: baseline characteristics of the randomized cohort","volume":"23","author":"Diabetes Prevention Program (DPP) Research Group","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0018|cit19","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2337\/diacare.22.4.623","article-title":"The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes","volume":"22","author":"Diabetes Prevention Program (DPP) Research Group","year":"1999","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2337\/dc11-1468","article-title":"The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP\/DPPOS","volume":"35","author":"Diabetes Prevention Program Research G","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Diabetes Prevention Program Research Group Changes in albumin excretion in the Diabetes Prevention Program Diabetes Care April 2009 720 5","DOI":"10.2337\/dc08-1400"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Diabetes Prevention Program Research Group Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program Diabetes Care April 2003 977 80.","DOI":"10.2337\/diacare.26.4.977"},{"issue":"12","key":"10.1002\/14651858.CD008558.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1007\/s11606-012-2122-5","article-title":"Impact of lifestyle intervention and metformin on health-related quality of life: the diabetes prevention program randomized trial","volume":"27","author":"Florez","year":"2012","journal-title":"Journal of General Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/dom.12220","article-title":"Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance","volume":"16","author":"Florez","year":"2014","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0025|cit25","doi-asserted-by":"crossref","unstructured":"Fujimoto WY Jablonski KA Bray GA Kriska A Barrett-Connor E Haffner S Body size and shape changes and the risk of diabetes in the diabetes prevention program Diabetes June 2007 1680 5","DOI":"10.2337\/db07-0009"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0026|cit26","unstructured":"Fujimoto WY. Diabetes Prevention Program Research Group Background and recruitment data for the U.S. Diabetes Prevention Program Diabetes Care June 2000 876"},{"issue":"1","key":"10.1002\/14651858.CD008558.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00125-018-4748-2","article-title":"Non-traditional biomarkers and incident diabetes in the Diabetes Prevention Program: comparative effects of lifestyle and metformin interventions","volume":"62","author":"Goldberg","year":"2019","journal-title":"Diabetologia"},{"issue":"1","key":"10.1002\/14651858.CD008558.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/CIRCULATIONAHA.116.025483","article-title":"Effect of long-term metformin and lifestyle in the Diabetes Prevention Program and Its Outcome Study on coronary artery calcium","volume":"136","author":"Goldberg","year":"2017","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2337\/dc08-0494","article-title":"Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group","volume":"32","author":"Goldberg","year":"2009","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1002\/14651858.CD008558.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.2337\/dc13-2471","article-title":"Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes","volume":"37","author":"Goldberg","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Goldberg RB Mather K Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program Arteriosclerosis, Thrombosis and Vascular Biology September 2012 2077 90","DOI":"10.1161\/ATVBAHA.111.241893"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2337\/diabetes.54.5.1566","article-title":"Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance","volume":"54","author":"Haffner","year":"2005","journal-title":"Diabetes"},{"issue":"3","key":"10.1002\/14651858.CD008558.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2337\/db14-0333","article-title":"Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS)","volume":"64","author":"Hamman","year":"2015","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0036|cit34","doi-asserted-by":"crossref","unstructured":"Herman WH The cost-effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study Clinical Diabetes and Endocrinology 2015","DOI":"10.1186\/s40842-015-0009-1"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0034|cit35","unstructured":"Herman WH Edelstein SL Ratner RE Montez MG Ackermann RT Orchard TJ Effectiveness and cost-effectiveness of diabetes prevention among adherent participants American Journal of Managed Care 2013 194 202"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0035|cit36","doi-asserted-by":"crossref","unstructured":"Herman WH Hoerger TJ Brandle M Hicks K Sorensen S Zhang P The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance Annals of Internal Medicine March 2005 323 32","DOI":"10.7326\/0003-4819-142-5-200503010-00007"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2337\/diacare.26.1.36","article-title":"Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program","volume":"26","author":"Hernan","year":"2003","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD008558.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2337\/db15-0950","article-title":"Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants","volume":"65","author":"Hivert","year":"2016","journal-title":"Diabetes"},{"issue":"12","key":"10.1002\/14651858.CD008558.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1111\/dme.12500","article-title":"Long-term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study","volume":"31","author":"Jaacks","year":"2014","journal-title":"Diabetic Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008558.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1210\/jc.2017-01829","article-title":"Androgens, irregular menses, and risk of diabetes and coronary artery calcification in the Diabetes Prevention Program","volume":"103","author":"Kim","year":"2018","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.psyneuen.2016.06.009","article-title":"Testosterone and depressive symptoms among men in the Diabetes Prevention Program","volume":"72","author":"Kim","year":"2016","journal-title":"Psychoneuroendocrinology"},{"issue":"9","key":"10.1002\/14651858.CD008558.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1210\/jc.2017-00967","article-title":"Changes in visceral adiposity, subcutaneous adiposity, and sex hormones in the Diabetes Prevention Program","volume":"102","author":"Kim","year":"2017","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"8","key":"10.1002\/14651858.CD008558.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.2337\/diabetes.54.8.2404","article-title":"Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin","volume":"54","author":"Kitabchi","year":"2005","journal-title":"Diabetes"},{"issue":"6","key":"10.1002\/14651858.CD008558.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"9707","key":"10.1002\/14651858.CD008558.pub2-BIB0045|cit45","first-page":"2054","article-title":"10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study","volume":"374","author":"Knowler","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"Knowler WC Hamman RF Edelstein SL Barrett-Connor E Ehrmann DA Walker EA Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program Diabetes 2005 1150 6","DOI":"10.2337\/diabetes.54.4.1150"},{"issue":"1","key":"10.1002\/14651858.CD008558.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2337\/dc14-0886","article-title":"HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial","volume":"38","author":"Knowler WC. Diabetes Prevention Program (DPP) Research Group","year":"2015","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2337\/db06-0918","article-title":"Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program","volume":"56","author":"Lachin","year":"2007","journal-title":"Diabetes"},{"issue":"7","key":"10.1002\/14651858.CD008558.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"958","DOI":"10.2337\/dc16-2376","article-title":"Metformin, lifestyle intervention, and cognition in the Diabetes Prevention Program Outcomes Study","volume":"40","author":"Luchsinger","year":"2017","journal-title":"Diabetes Care"},{"issue":"0","key":"10.1002\/14651858.CD008558.pub2-BIB0050|cit50","first-page":"A344","article-title":"Physical function decline in the diabetes prevention program outcome study","volume":"63","author":"Ma","year":"2014","journal-title":"Diabetes"},{"issue":"1","key":"10.1002\/14651858.CD008558.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11136-013-0436-3","article-title":"Impact of diagnosis of diabetes on health-related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study","volume":"23","author":"Marrero","year":"2014","journal-title":"Quality of Life Research"},{"issue":"12","key":"10.1002\/14651858.CD008558.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s11606-013-2548-4","article-title":"Early response to preventive strategies in the Diabetes Prevention Program","volume":"28","author":"Maruthur","year":"2013","journal-title":"Journal of General Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"980","DOI":"10.2337\/db07-1419","article-title":"Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program","volume":"57","author":"Mather","year":"2008","journal-title":"Diabetes"},{"issue":"10","key":"10.1002\/14651858.CD008558.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1210\/jc.2015-2328","article-title":"Steroid sex hormones, sex hormone-binding globulin, and diabetes incidence in the Diabetes Prevention Program","volume":"100","author":"Mather","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD008558.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/PSY.0000000000000380","article-title":"Replication of the association of BDNF and MC4R variants with dietary intake in the Diabetes Prevention Program","volume":"79","author":"McCaffery","year":"2017","journal-title":"Psychosomatic Medicine"},{"issue":"7 Suppl 2","key":"10.1002\/14651858.CD008558.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1097\/01.ASN.0000070140.62190.97","article-title":"The diabetes prevention program and its global implications","volume":"14","author":"Molitch","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0057|cit57","unstructured":"NCT00004992 Diabetes Prevention Program clinicaltrials.gov\/ct2\/show\/NCT00004992"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0058|cit58","unstructured":"NCT00038727 Diabetes Prevention Program Outcomes Study (DPPOS) clinicaltrials.gov\/ct2\/show\/NCT00038727"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0059|cit59","unstructured":"NCT03757910 Brain imaging in the Diabetes Prevention Program Outcomes Study (DPPOS-Brain) clinicaltrials.gov\/ct2\/show\/NCT03757910"},{"issue":"11","key":"10.1002\/14651858.CD008558.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S2213-8587(15)00291-0","article-title":"Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study","volume":"3","author":"Nathan","year":"2015","journal-title":"Lancet. Diabetes & endocrinology"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ypmed.2015.05.017","article-title":"The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program","volume":"77","author":"O'Brien","year":"2015","journal-title":"Preventive Medicine"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0062|cit62","doi-asserted-by":"crossref","unstructured":"Orchard TJ Temprosa M Barrett-Connor E Fowler SE Goldberg RB Mather KJ et al. Diabetes Prevention Program Outcomes Study Research Group Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study Diabetic Medicine January 2013 46 55","DOI":"10.1111\/j.1464-5491.2012.03750.x"},{"issue":"9","key":"10.1002\/14651858.CD008558.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2337\/dc09-0523","article-title":"Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program","volume":"32","author":"Perreault","year":"2009","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD008558.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2337\/dc07-2390","article-title":"Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program","volume":"31","author":"Perreault","year":"2008","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1002\/14651858.CD008558.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/dme.13453","article-title":"Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS)","volume":"34","author":"Perreault","year":"2017","journal-title":"Diabetic Medicine"},{"issue":"9833","key":"10.1002\/14651858.CD008558.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(12)60525-X","article-title":"Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study","volume":"379","author":"Perreault","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD008558.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/iju.12654","article-title":"Long-term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study","volume":"22","author":"Phelan","year":"2015","journal-title":"International Journal of Urology"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2337\/diacare.28.4.888","article-title":"Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program","volume":"28","author":"Ratner","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4158\/EP.12.S1.20","article-title":"An update on the Diabetes Prevention Program","volume":"12 Suppl 1","author":"Ratner","year":"2006","journal-title":"Endocrine Practice"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0197-2456(01)00184-2","article-title":"The Diabetes Prevention Program: recruitment methods and results","volume":"23","author":"Rubin","year":"2002","journal-title":"Controlled Clinical Trials"},{"issue":"11","key":"10.1002\/14651858.CD008558.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.3945\/jn.117.252395","article-title":"A high-carbohydrate, high-fiber, low-fat diet results in weight loss among adults at high risk of type 2 diabetes","volume":"147","author":"Sylvetsky","year":"2017","journal-title":"Journal of Nutrition"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2337\/dc11-1299","article-title":"Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study","volume":"35","author":"The Diabetes Prevention Program Research Group","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.2337\/diacare.26.9.2518","article-title":"Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes","volume":"26","author":"The Diabetes Prevention Program Research Group","year":"2003","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD008558.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/oby.2008.224","article-title":"Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program","volume":"16","author":"West","year":"2008","journal-title":"Obesity (Silver Spring, Md.)"},{"issue":"9","key":"10.1002\/14651858.CD008558.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/oby.2004.179","article-title":"Achieving weight and activity goals among diabetes prevention program lifestyle participants","volume":"12","author":"Wing","year":"2004","journal-title":"Obesity research"},{"issue":"2","key":"10.1002\/14651858.CD008558.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/PSY.0000000000000535","article-title":"Depressive symptoms, antidepressant medication use, and inflammatory markers in the Diabetes Prevention Program","volume":"80","author":"Groot","year":"2018","journal-title":"Psychosomatic Medicine"},{"issue":"30","key":"10.1002\/14651858.CD008558.pub2-BIB0077|cit77","first-page":"6562","article-title":"Effect of medicine and non-medicine intervention on the outcomes of patients with impaired glucose tolerance: 5-year follow-up","volume":"8","author":"Fang","year":"1999","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0078|cit78","unstructured":"NCT00279240 Life style modifications prevents type 2 diabetes in Asian Indians https:\/\/clinicaltrials.gov\/show\/NCT00279240"},{"issue":"10","key":"10.1002\/14651858.CD008558.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.2337\/dc09-1150","article-title":"Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP-1 and IDPP-2)","volume":"33","author":"Ramachandran","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00125-005-0097-z","article-title":"The Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)","volume":"49","author":"Ramachandran","year":"2006","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD008558.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.diabres.2006.08.009","article-title":"Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians--Result of Indian diabetes prevention programme","volume":"76","author":"Ramachandran","year":"2007","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"10","key":"10.1002\/14651858.CD008558.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.2337\/dc07-0150","article-title":"Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP)","volume":"30","author":"Ramachandran","year":"2007","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD008558.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3132\/dvdr.2008.005","article-title":"Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme","volume":"5","author":"Snehalatha","year":"2008","journal-title":"Diabetes & Vascular Disease Research"},{"issue":"10","key":"10.1002\/14651858.CD008558.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.2337\/dc09-0676","article-title":"Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1)","volume":"32","author":"Snehalatha","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/867604","article-title":"Effect of intervention in subjects with high risk of diabetes mellitus in Pakistan","volume":"2012","author":"Iqbal Hydrie","year":"2012","journal-title":"Journal of Nutrition and Metabolism"},{"issue":"8","key":"10.1002\/14651858.CD008558.pub2-BIB0086|cit86","first-page":"920","article-title":"Effects of metformin on serum c-reactive protein and insulin sensitivity index in prediabetic patients","volume":"16","author":"Ji","year":"2011","journal-title":"Chinese Journal of Clinical Pharmacology and Therapeutics [\u4e2d\u56fd\u4e34\u5e8a\u836f\u7406\u5b66\u4e0e\u6cbb\u7597\u5b66]"},{"issue":"11","key":"10.1002\/14651858.CD008558.pub2-BIB0087|cit87","first-page":"969","article-title":"Changes in insulin resistance and islet beta cell function in patients with impaired fasting glucose after intervention","volume":"34","author":"Jin","year":"2009","journal-title":"Journal of Bengbu Medical College [\u868c\u57e0\u533b\u5b66\u9662\u5b66\u62a5]"},{"issue":"6","key":"10.1002\/14651858.CD008558.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1464-5491.1999.00090.x","article-title":"Effect of metformin on patients with impaired glucose tolerance","volume":"16","author":"Li","year":"1999","journal-title":"Diabetic Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008558.pub2-BIB0089|cit89","first-page":"254","article-title":"Intervention of participants with composite impaired glucose regulation and obesity by Metformin","volume":"33","author":"Li","year":"2009","journal-title":"Central China Medical Journal [\u534e\u4e2d\u533b\u5b66\u6742\u5fd7]"},{"issue":"11","key":"10.1002\/14651858.CD008558.pub2-BIB0090|cit90","first-page":"145","article-title":"Clinical observation of acarbose and metformin in patients with impaired glucose tolerance","volume":"18","author":"Liao","year":"2012","journal-title":"Contemporary Medicine [\u5f53\u4ee3\u533b\u5b66]"},{"issue":"6","key":"10.1002\/14651858.CD008558.pub2-BIB0091|cit91","first-page":"21","article-title":"Intervention of metformin and dietary fiber in the development of type 2 diabetes in people with low glucose tolerance","volume":"-","author":"Lu","year":"2002","journal-title":"Chinese Journal of Diabetes [\u4e2d\u56fd\u7cd6\u5c3f\u75c5\u6742\u5fd7]"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0092|cit92","unstructured":"Lu YM Effects comparison between pre-diabetes lifestyle intervention and drug intervention Zhengzhou University Master Thesis 2010"},{"issue":"11","key":"10.1002\/14651858.CD008558.pub2-BIB0093|cit93","first-page":"609","article-title":"Prevention of type 2 diabetes in the prediabetic population","volume":"103","author":"Maji","year":"2005","journal-title":"Journal of the Indian Medical Association"},{"issue":"363","key":"10.1002\/14651858.CD008558.pub2-BIB0094|cit94","first-page":"Abstract 31","article-title":"Short term effects (2 years) of oral treatment for diabetes in the borderline impairment of oral glucose tolerance test","volume":"10","author":"Eschwege E. French Study Group for Diabetes Epidemiology (A.F.E.D.I.A.)","year":"1974","journal-title":"Diabetologia"},{"issue":"5","key":"10.1002\/14651858.CD008558.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/BF01219646","article-title":"Effect of oral hypoglycaemic drugs on glucose tolerance and insulin secretion in borderline diabetic patients","volume":"15","author":"Papoz","year":"1978","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD008558.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/osp4.157","article-title":"Association of changes in mental health with weight loss during intensive lifestyle intervention: does the timing matter?","volume":"4","author":"Alhalel","year":"2018","journal-title":"Obesity Science and Practice"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0097|cit97","unstructured":"NCT02088034 Intervention to promote weight loss in Latinas At-risk for Diabetes clinicaltrials.gov\/ct2\/show\/NCT02088034"},{"issue":"6","key":"10.1002\/14651858.CD008558.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.amepre.2017.01.008","article-title":"PREVENT-DM comparative effectiveness trial of lifestyle intervention and metformin","volume":"52","author":"O'Brien","year":"2017","journal-title":"American Journal of Preventive Medicine"},{"issue":"Pt B","key":"10.1002\/14651858.CD008558.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cct.2015.10.011","article-title":"The rationale, design, and baseline characteristics of PREVENT-DM: A community-based comparative effectiveness trial of lifestyle intervention and metformin among Latinas with prediabetes","volume":"45","author":"Perez","year":"2015","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0100|cit100","unstructured":"Wang BL Zhang LL Clinical observation of metformin in the treatment of prediabetes Collected papers of the 7th endocrine academic conference of Shanxi Medical Association [\u5c71\u897f\u7701\u533b\u5b66\u4f1a\u7b2c\u4e03\u5c4a\u5185\u5206\u6ccc\u5b66\u672f\u4f1a\u8bae\u8bba\u6587\u96c6] Tai Yuan [\u592a\u539f] Shanxi Medical Association [\u5c71\u897f\u7701\u533b\u5b66\u4f1a] 2009 38 9"},{"issue":"5","key":"10.1002\/14651858.CD008558.pub2-BIB0101|cit101","first-page":"370","article-title":"Observation on the clinical effect of different intervention methods in patients with impaired glucose regulation","volume":"33","author":"Zeng","year":"2013","journal-title":"Health Research [\u5065\u5eb7\u7814\u7a76]"},{"issue":"1","key":"10.1002\/14651858.CD008558.pub2-BIB0102|cit102","first-page":"27","article-title":"Clinical observation of metformin in the treatment of obesity with prediabetes (46 cases report attached)","volume":"27","author":"Zhao","year":"2013","journal-title":"Journal of Hubei University of Science and Technology (Medical Sciences) [\u6e56\u5317\u79d1\u6280\u5b66\u9662\u5b66\u62a5(\u533b\u5b66\u7248)]"},{"issue":"1","key":"10.1002\/14651858.CD008558.pub2-BIB0103|cit103","first-page":"4019","article-title":"The efficacy of metformin in the treatment of hypertensive subjects with impaired glucose tolerance: Its effects on insulin sensitivity, blood pressure, carbohydrate and lipid metabolism","volume":"9","author":"Acbay","year":"1996","journal-title":"Klinik Gelisim"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0104|cit104","first-page":"24","article-title":"Metformin and impaired glucose tolerance in overweight persons with schizophrenia","volume":"37","author":"Ballon","year":"2011","journal-title":"Oxford University Press"},{"issue":"2","key":"10.1002\/14651858.CD008558.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.metabol.2004.08.018","article-title":"Differential regulation of insulin action and tumor necrosis factor alpha system activity by metformin","volume":"54","author":"Biarn\u00e9s","year":"2005","journal-title":"Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD008558.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00129784-200707030-00007","article-title":"Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome","volume":"7","author":"Bulc\u00e3o","year":"2007","journal-title":"American Journal of Cardiovascular Drugs"},{"issue":"8","key":"10.1002\/14651858.CD008558.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1210\/jc.2004-0019","article-title":"The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomised clinical trial","volume":"89","author":"Caballero","year":"2004","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"10","key":"10.1002\/14651858.CD008558.pub2-BIB0108|cit108","first-page":"905","article-title":"Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidaemia and impaired glucose tolerance","volume":"35","author":"Celik","year":"2012","journal-title":"Journal of Endocrinological Investigation"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1463-1326.2006.00606.x","article-title":"Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin","volume":"8","author":"Chazova","year":"2006","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD008558.pub2-BIB0110|cit110","first-page":"48","article-title":"Metformin combined with lifestyle guidance in the treatment of 34 patients with obesity prediabetes","volume":"9","author":"Chen","year":"2013","journal-title":"Journal of Practical Diabetology [\u5b9e\u7528\u7cd6\u5c3f\u75c5\u6742\u5fd7]"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0111|cit111","unstructured":"ChiCTR-TRC-09000548 A randomized controlled trial for investigating the protective effects of fenofibrate on prediabetes with hypertriglyceridemia apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR-TRC-09000548"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0112|cit112","unstructured":"CTRI\/2013\/02\/003417 Restudy of the PURSE HIS Population for the prevalence of risk factors causing blood vessel damage to heart muscle, brain tissue or peripheral tissue and to give advice on diet, exercise and if necessary small dose of drug to prevent conversion of Pre-Diabetes to Diabetes apps.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2013\/02\/003417"},{"issue":"1","key":"10.1002\/14651858.CD008558.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1291\/hypres.30.23","article-title":"Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes","volume":"30","author":"Eguchi","year":"2007","journal-title":"Hypertension Research"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.regpep.2012.12.005","article-title":"Comparative effects of metformin and pioglitazone on omenti and leptin concentrations in patients with newly diagnosed diabetes: a randomised clinical trial","volume":"182","author":"Esteghamati","year":"2013","journal-title":"Regulatory Peptides"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0115|cit115","unstructured":"EUCTR2018-000650-21-ES Clinical trial to evaluate biomarkers of vascular aging apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2018-000650-21-ES"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0116|cit116","unstructured":"EUCTR2008-004497-40-GB The effect of metformin on weight and cardiovascular risk markers in abdomenally obese subjects with impaired fasting glucose previously treated for 12 months with either rimonabant or placebo - use of metformin following weight loss and improvement in CV risk apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2008-004497-40-GB"},{"issue":"2","key":"10.1002\/14651858.CD008558.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1210\/jcem.87.2.8261","article-title":"Ovarian function and metabolic factors in women with oligomenorrhoea treated with metformin in a randomised double blind placebo-controlled trial","volume":"87","author":"Fleming","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0118|cit118","first-page":"143","article-title":"Crossover and double blind study with metformin and rosiglitazone in impaired glucose tolerance subjects","volume":"46","author":"Flores-Saenz","year":"2003","journal-title":"Proceedings of the Western Pharmacology Society"},{"issue":"9","key":"10.1002\/14651858.CD008558.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.metabol.2012.02.003","article-title":"Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomised clinical trial","volume":"61","author":"G\u00f3mez-D\u00edaz","year":"2012","journal-title":"Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD008558.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/01.sla.0000152013.23032.d1","article-title":"Influence of metformin on glucose intolerance and muscle catabolism following severe burn injury","volume":"241","author":"Gore","year":"2005","journal-title":"Annals of Surgery"},{"issue":"1","key":"10.1002\/14651858.CD008558.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2337\/dc10-0531","article-title":"Pharmacological treatment of the pathogenetic defects in type 2 diabetes: The randomised multicenter South Danish diabetes study","volume":"34","author":"Gram","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0122|cit122","first-page":"S22","article-title":"Diabetes prevention with lifestyle, linagliptin and metformin in patients with prediabetes: The PRELLIM project","volume":"61","author":"Guardado-Mendoza","year":"2018","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0123|cit123","first-page":"334","article-title":"A randomised, placebo controlled trial with metformin in patients with NAFLD","volume":"48","author":"Haukeland","year":"2008","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0124|cit124","first-page":"433","article-title":"Characteristic of metformin for treatment of impaired glucose tolerance","volume":"63 Suppl 2","author":"Ishida","year":"2005","journal-title":"Nihon Rinsho"},{"issue":"10","key":"10.1002\/14651858.CD008558.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1055\/s-0029-1202792","article-title":"Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome","volume":"117","author":"Kato","year":"2009","journal-title":"Experimental and Clinical Endocrinology & Diabetes"},{"issue":"64","key":"10.1002\/14651858.CD008558.pub2-BIB0126|cit126","first-page":"1327","article-title":"Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomised trial","volume":"11","author":"Kelly","year":"2012","journal-title":"Cardiovascular Diabetology"},{"issue":"1","key":"10.1002\/14651858.CD008558.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1210\/jc.2012-2710","article-title":"Metformin in obese children and adolescents: the MOCA trial","volume":"98","author":"Kendall","year":"2013","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD008558.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3109\/09513590.2010.530706","article-title":"Inflammatory-metabolic parameters in obese and non-obese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment","volume":"27","author":"Kilic","year":"2011","journal-title":"Gynecological Endocrinology"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0129|cit129","first-page":"207","article-title":"Treatment of subjects with obesity and impaired fasting glucose with metformin","volume":"9","author":"Koev","year":"2004","journal-title":"Endokrinologya"},{"issue":"2","key":"10.1002\/14651858.CD008558.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.atherosclerosis.2012.09.034","article-title":"Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose","volume":"225","author":"Krysiak","year":"2012","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1002\/14651858.CD008558.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1046\/j.1464-5491.2001.00539.x","article-title":"Metabolic effects of metformin in patients with impaired glucose tolerance","volume":"18","author":"Lehtovirta","year":"2001","journal-title":"Diabetic Medicine"},{"issue":"9","key":"10.1002\/14651858.CD008558.pub2-BIB0132|cit132","first-page":"830","article-title":"Effect of renshen jianxin capsule for alleviating insulin resistance in patients with coronary heart disease and glucose tolerance impairment","volume":"29","author":"Li","year":"2009","journal-title":"Chinese Journal of Integrated Traditional & Western Medicine"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0133|cit133","first-page":"151","article-title":"Safety and feasibility of treatment with metformin in patients with TIA or minor ischaemic stroke and impaired glucose tolerance: a randomised open-label phase II trial","volume":"17(Suppl 6)","author":"Hertog","year":"2009","journal-title":"Cerebrovascular Diseases"},{"issue":"6","key":"10.1002\/14651858.CD008558.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s12325-011-0022-4","article-title":"Outcome of intensive integrated intervention in participants with impaired glucose regulation in China","volume":"28","author":"Lu","year":"2011","journal-title":"Advances in Therapy"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1139\/apnm-2012-0433","article-title":"Effect of metformin on substrate utilization after exercise training in adults with impaired glucose tolerance","volume":"38","author":"Malin","year":"2013","journal-title":"Applied Physiology, Nutrition, & Metabolism"},{"issue":"11","key":"10.1002\/14651858.CD008558.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/jama.2016.17844","article-title":"Metformin for prediabetes","volume":"317","author":"Anonymous","year":"2017","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD008558.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1046\/j.1464-5491.1999.00120.x","article-title":"Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance","volume":"16","author":"Morel","year":"1999","journal-title":"Diabetic Medicine"},{"issue":"Suppl 74\/I","key":"10.1002\/14651858.CD008558.pub2-BIB0138|cit138","first-page":"12","article-title":"Effect of metformin on insulin-resistance in obese patients with glucose-intolerance","volume":"126","author":"Morel","year":"1996","journal-title":"Schweizerische medizinische Wochenschrift"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0139|cit139","unstructured":"NCT00108615 Effects of insulin sensitizers in subjects with impaired glucose tolerance clinicaltrials.gov\/ct2\/show\/NCT00108615"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0140|cit140","unstructured":"NCT02338193 Dapagliflozin and metformin, alone and in combination, in overweight\/obese prior GDM women (DAPA-GDM) clinicaltrials.gov\/ct2\/show\/NCT02338193"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0141|cit141","unstructured":"NCT03258723 Diabetes prevention with lifestyle intervention and metformin escalation (LIME) clinicaltrials.gov\/ct2\/show\/NCT03258723"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0142|cit142","unstructured":"NCT03503942 The pre-diabetes interventions and continued tracking to ease-out diabetes (Pre-DICTED) program https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03503942"},{"issue":"5","key":"10.1002\/14651858.CD008558.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1210\/jc.2012-4251","article-title":"Optimal macronutrient content of the diet for adolescents with prediabetes; RESIST a randomised control trial","volume":"98","author":"Garnett","year":"2013","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD008558.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1463-1326.2011.01481.x","article-title":"Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance","volume":"14","author":"Retnakaran","year":"2012","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD008558.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1463-1326.2004.00385.x","article-title":"Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes","volume":"7","author":"Rodr\u00edguez-Moctezuma","year":"2005","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"12","key":"10.1002\/14651858.CD008558.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1464-5491.2009.02857.x","article-title":"Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18)","volume":"26","author":"Scheen","year":"2009","journal-title":"Diabetic Medicine"},{"issue":"11","key":"10.1002\/14651858.CD008558.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.2337\/diacare.27.11.2768","article-title":"Impact of metformin on glucose metabolism in nondiabetic, obese African Americans: A placebo-controlled, 24-month randomised study","volume":"27","author":"Schuster","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0148|cit148","unstructured":"SLCTR\/2016\/026 Effects of metformin and lifestyle modifications on the progression of the atherosclerosis among individuals with impaired glucose tolerance slctr.lk\/trials\/slctr-2016-026"},{"issue":"10","key":"10.1002\/14651858.CD008558.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.2337\/diacare.21.10.1720","article-title":"The STOP-NIDDM trial: An international study on the efficacy of an alpha- glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: Rationale, design, and preliminary screening data","volume":"21","author":"Chiasson","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0150|cit150","unstructured":"Stroup S Effect of metformin on weight in patients with schizophrenia with impaired fasting glucose Neuropsychopharmacology 2013 S41"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0151|cit151","first-page":"S500","article-title":"A comparative study with metformin and pioglitazone versus metformin alone in nonalcoholic fatty liver disease in newly detected glucose intolerant patients","volume":"55","author":"Sultana","year":"2012","journal-title":"Diabetologia"},{"issue":"3","key":"10.1002\/14651858.CD008558.pub2-BIB0152|cit152","first-page":"78","article-title":"UK Prospective Diabetes Study","volume":"5","author":"Turner","year":"1996","journal-title":"Diabetes und Stoffwechsel"},{"issue":"2","key":"10.1002\/14651858.CD008558.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s13142-016-0447-z","article-title":"The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results","volume":"7","author":"Vitolins","year":"June 2017","journal-title":"Translational Behavioral Medicine"},{"issue":"11","key":"10.1002\/14651858.CD008558.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/j.1464-5491.2010.03107.x","article-title":"Regression to normoglycaemia by fenofibrate in pre-diabetic subjects complicated with hypertriglyceridaemia: a prospective randomised controlled trial","volume":"27","author":"Wan","year":"2010","journal-title":"Diabetic Medicine"},{"issue":"9735","key":"10.1002\/14651858.CD008558.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(10)60746-5","article-title":"Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study","volume":"376","author":"Zinman","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0156|cit156","unstructured":"ChiCTR-IPR-17012309 The effect of metformin on the number and function of the circulating endothelial progenitor cells in prediabetic patients www.chictr.org.cn\/showproj.aspx?proj=21001"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0157|cit157","unstructured":"Anonymous Early Diabetes Intervention Trial https:\/\/www.dtu.ox.ac.uk\/EDIT\/"},{"issue":"Suppl. 1","key":"10.1002\/14651858.CD008558.pub2-BIB0158|cit158","first-page":"A73","article-title":"Possible prevention of type 2 diabetes with acarbose or metformin over three years","volume":"43","author":"Citro\u00ebn","year":"2000","journal-title":"Diabetologia"},{"issue":"Suppl. 1","key":"10.1002\/14651858.CD008558.pub2-BIB0159|cit159","first-page":"A16","article-title":"Results from the early diabetes intervention trial","volume":"52","author":"Holman","year":"2003","journal-title":"Diabetes"},{"issue":"Suppl. 2","key":"10.1002\/14651858.CD008558.pub2-BIB0160|cit160","first-page":"15","article-title":"Six-years results from the Early Diabetes Intervention Trial","volume":"20","author":"Holman","year":"2003","journal-title":"Diabetic Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008558.pub2-BIB0161|cit161","first-page":"157A","article-title":"Early Diabetes Intervention Trial","volume":"46","author":"Holman","year":"1997","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0162|cit162","unstructured":"Holman RR North BV Tunbridge FKE Early diabetes intervention trial Diabetologia 1997 A17"},{"issue":"Suppl. 1","key":"10.1002\/14651858.CD008558.pub2-BIB0163|cit163","first-page":"450","article-title":"Possible prevention of type 2 diabetes with acarbose or metformin","volume":"49","author":"Holman","year":"2000","journal-title":"Diabetes YR"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0164|cit164","unstructured":"ISRCTN96631607 Early diabetes intervention trial apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ISRCTN96631607"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0165|cit165","unstructured":"Kim JI Stevens RJ Holman RR The haemoglobin glycation index is reproducible in dysglycaemic individual but is not explained by post-challenge plasma glucose levels [Abstract] Diabetologia 2004;47(suppl 1):A122"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0166|cit166","article-title":"Insulin resistance and mild cognitive impairment (IRMCI) study","volume":"-","author":"NCT02409238","journal-title":"clinicaltrials.gov\/ct2\/show\/NCT02409238"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0167|cit167","first-page":"A687","article-title":"Preventing the development of type 2 diabetes in subjects at high risk in western Mexico, using metformin and changes in lifestyle, followed 10 years","volume":"64","author":"Polanco","year":"2015","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0168|cit168","unstructured":"CTRI\/2017\/09\/009635 A study of life style modification with and without metformin in prediabetic subjects www.ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=16184"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0172|cit169","unstructured":"Unpublished protocol Provided by the investigators"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0169|cit170","unstructured":"EUCTR2013-000418-39-AT Early prevention of diabetes complications in people with hyperglycaemia in Europe - e-PREDICE apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2013-000418-39-AT"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0170|cit171","unstructured":"EudraCT 2013-000418-39 Early prevention of diabetes complications in people with hyperglycaemia in Europe www.clinicaltrialsregister.eu\/ctr-search\/search?query=2013-000418-39"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0171|cit172","unstructured":"NCT03222765 Prevention of microvascular complications in prediabetes e-PREDICE Study (ePREDICE) clinicaltrials.gov\/ct2\/show\/NCT03222765"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0173|cit173","unstructured":"ePRECIDE The project www.epredice.eu\/en\/the-project"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0174|cit174","doi-asserted-by":"crossref","unstructured":"Espinoza SE Musi N Wang CP Michalek J Orsak B Romo T Rationale and study design of a randomized clinical trial of metformin to prevent frailty in older adults with pre-diabetes Journals of Gerontology Biological Sciences and Medical Sciences March 2019","DOI":"10.1093\/gerona\/glz078"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0175|cit175","unstructured":"NCT02570672 Metformin for preventing frailty in high-risk older adults clinicaltrials.gov\/ct2\/show\/NCT02570672"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0176|cit176","first-page":"No page numbers","article-title":"Efficacy of metformin in preventing progression to diabetes in Chinese subjects with impaired glucose regulation: protocol for a multicenter, open-label, randomized, controlled clinical study","volume":"Epub ahead of p","author":"Ji","year":"September 2019","journal-title":"Diabetes Obesity Metabolism"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0177|cit177","unstructured":"NCT03441750 Efficacy of metformin in preventing diabetes in China (ChinaDPP) clinicaltrials.gov\/ct2\/show\/NCT03441750"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0178|cit178","unstructured":"JPRN-UMIN000018995 Metformin therapy for East Asian women with recent gestational diabetes mellitus and glucose abnormalities: a multicenter, randomised, open-label trial upload.umin.ac.jp\/cgi-open-bin\/icdr_e\/ctr_view.cgi?recptno=R000021900"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0179|cit179","unstructured":"NCT01779362 RISE adult medication study (RISE Adult) clinicaltrials.gov\/ct2\/show\/NCT01779362"},{"issue":"3","key":"10.1002\/14651858.CD008558.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2337\/dc13-1879","article-title":"Restoring Insulin Secretion (RISE): design of studies of beta-cell preservation in prediabetes and early type 2 diabetes across the life span","volume":"37","author":"Nadeau","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0181|cit181","unstructured":"NCT01804049 Metformin and muscle in insulin-resistant older veterans (M&M) clinicaltrials.gov\/ct2\/show\/NCT01804049"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0182|cit182","unstructured":"NCT02915198 Investigation of metformin in pre-diabetes on atherosclerotic cardiovascular outcomes (VA-IMPACT) clinicaltrials.gov\/ct2\/show\/NCT02915198"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0183|cit183","unstructured":"NCT02969798 Pre-diabetes in subject with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) clinicaltrials.gov\/show\/NCT02969798"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0184|cit184","unstructured":"NCT03194009 Prudente; diabetes prevention via exercise, nutrition and treatment (PRuDENTE) clinicaltrials.gov\/ct2\/show\/NCT03194009"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0185|cit185","unstructured":"NCT02981121 Hospital-based diabetes prevention study in Korea clinicaltrials.gov\/ct2\/show\/NCT02981121"},{"issue":"1","key":"10.1002\/14651858.CD008558.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4093\/dmj.2018.0033","article-title":"Hospital-based Korean diabetes prevention study: a prospective, multi-center, randomized, open-label controlled study","volume":"43","author":"Rhee","year":"2019","journal-title":"Diabetes and Metabolism Journal"},{"issue":"5","key":"10.1002\/14651858.CD008558.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2337\/db05-1200","article-title":"Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study","volume":"55","author":"Abdul-Ghani","year":"2006","journal-title":"Diabetes"},{"issue":"7","key":"10.1002\/14651858.CD008558.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2337\/diacare.20.7.1183","article-title":"Report of the Expert Committee on the diagnosis and classification of diabetes mellitus","volume":"20","author":"The Expert Committee on the diagnosis and classification of diabetes mellitus","year":"1997","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1002\/14651858.CD008558.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.2337\/diacare.26.11.3160","article-title":"Follow-up report on the diagnosis of diabetes mellitus","volume":"26","author":"The Expert Committee on the diagnosis and classification of diabetes mellitus","year":"2003","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008558.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.2337\/dc08-S012","article-title":"Standards of medical care in diabetes - 2008","volume":"31","author":"American Diabetes Association","year":"2008","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008558.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc10-S062","article-title":"Diagnosis and classification of diabetes mellitus","volume":"33","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008558.pub2-BIB0192|cit192","first-page":"S1","article-title":"Standards of medical care in diabetes-2015","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0193|cit193","first-page":"(Suppl 1)","article-title":"Standards of medical care in diabetes-2017","volume":"40","author":"American Diabetes Association","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.2337\/dc19-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes 2019","volume":"42 (Supplement","author":"American Diabetes Association","year":"January 2019","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0195|cit195","unstructured":"American Hospital Formulary Service (AHFS) Metformin hydrochloride American Hospital Formulary Service Drug Information. Bethesda, USA: American Society of Health-System Pharmacists, Inc. 1999"},{"issue":"7382","key":"10.1002\/14651858.CD008558.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/pon.3205","article-title":"Designing psycho-oncology randomised trials and cluster randomised trials: variance components and intra-cluster correlation of commonly used psychosocial measures","volume":"22","author":"Bell","year":"2013","journal-title":"Psychooncology"},{"issue":"1","key":"10.1002\/14651858.CD008558.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I\u00b2 is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0199|cit199","unstructured":"Borenstein M Prediction intervals www.meta-analysis.com\/prediction"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.2014.56.7503","article-title":"Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial","volume":"32","author":"Boutron","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0201|cit201","unstructured":"http:\/\/www.cdc.gov\/diabetes\/data\/statistics\/2014statisticsreport.html Assessed October 2015"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.metabol.2005.10.003","article-title":"The utility of fasting glucose for detection of prediabetes","volume":"55","author":"Cheng","year":"2006","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"-","key":"10.1002\/14651858.CD008558.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"8145","DOI":"10.1038\/srep08145","article-title":"Antihyperglycemic mechanism of metformin occurs via the AMPK\/LXRalpha\/POMC pathway","volume":"5","author":"Cho","year":"2015","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1002\/14651858.CD008558.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/jrsm.1090","article-title":"Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool","volume":"5","author":"Corbett","year":"2014","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0205|cit205","volume-title":"Molecules and Medicine","author":"Corey","year":"2007"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0206|cit206","unstructured":"Deeks JJ Higgins JP Altman DG (editors) on behalf of the Cochrane Statistical Methods Group Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0026-0495(89)90129-7","article-title":"Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake","volume":"38","author":"DeFronzo","year":"1989","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7326\/0003-4819-131-4-199908170-00008","article-title":"Pharmacologic therapy for type 2 diabetes mellitus","volume":"131","author":"DeFronzo","year":"1999","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008558.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"9702","key":"10.1002\/14651858.CD008558.pub2-BIB0210|cit210","first-page":"1677","article-title":"10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study","volume":"374","author":"Knowler","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0211|cit211","unstructured":"Diabetes UK Blood Sugar Converter https:\/\/www.diabetes.co.uk\/blood-sugar-converter.html"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0212|cit212","unstructured":"Diabetes UK Convert Whole Blood Results to Plasma Readings https:\/\/www.diabetes.co.uk\/whole-blood-readings-to-plasma-converter.html"},{"issue":"6","key":"10.1002\/14651858.CD008558.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Diabetes Prevention Program Research Group","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008558.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nm.3787","article-title":"Metformin activates a duodenal AMPK-dependent pathway to lower hepatic glucose production in rats","volume":"21","author":"Duca","year":"2015","journal-title":"Nature Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2337\/dc13-2195","article-title":"Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis","volume":"37","author":"Dunkley","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0216|cit216","unstructured":"FDA FDA Approved Drug Products https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/pre96\/020357Orig1s000rev.pdf. Assessed 20th September 2019"},{"issue":"18","key":"10.1002\/14651858.CD008558.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Tuomilehto","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008558.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MAJ.0000000000000223","article-title":"Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice","volume":"348","author":"Gosmanov","year":"2014","journal-title":"American Journal of the Medical Sciences"},{"issue":"12","key":"10.1002\/14651858.CD008558.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1001\/jamainternmed.2017.6040","article-title":"Long-term sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials","volume":"177","author":"Haw","year":"2017","journal-title":"JAMA Internal Medicine"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0222|cit222","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0223|cit223","unstructured":"Higgins JP Deeks JJ Altman DG editor(s) on behalf of the Cochrane Statistical Methods Group Chapter 16: Special topics in statistics. In: Higgins JT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0224|cit224","unstructured":"Higgins JP Altman DG Sterne JA (editors) on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017 Available from training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"E201","DOI":"10.1503\/cmaj.120744","article-title":"Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors","volume":"185","author":"Hr\u00f3bjartsson","year":"2013","journal-title":"Canadian Medical Association Journal"},{"issue":"46","key":"10.1002\/14651858.CD008558.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"e4998","DOI":"10.1097\/MD.0000000000004998","article-title":"Lactic acidosis and the relationship with metformin usage: Case reports","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0227|cit227","unstructured":"International Conference on Harmonisation Expert Working Group International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice \/\/1997 CFR & ICH Guidelines PA 19063-2043 USA: Barnett International\/PAREXEL, 1997"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0228|cit228","volume-title":"International Diabetes Federation. IDF Diabetes Atlas, 6th ed.Brussels, Belgium","author":"International Diabetes Federation","year":"2013"},{"issue":"7","key":"10.1002\/14651858.CD008558.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2337\/dc09-9033","article-title":"International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes","volume":"32","author":"International Expert Committee","year":"2009","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD008558.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMcp1103643","article-title":"Clinical practice. Diagnosis of diabetes","volume":"367","author":"Inzucchi","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0231|cit231","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12916-015-0520-3","article-title":"Comparison of registered and published outcomes in randomized controlled trials: a systematic review","volume":"13","author":"Jones","year":"2015","journal-title":"BMC Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJMcpc1208154","article-title":"Case records of the Massachusetts General Hospital. Case 23-2013. A 54-year-old woman with abdominal pain, vomiting, and confusion","volume":"369","author":"Kalantar-Zadeh","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0233|cit233","doi-asserted-by":"publisher","first-page":"c365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD008558.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"227","DOI":"10.7326\/0003-4819-92-2-227","article-title":"Lactate homeostasis and lactic acidosis","volume":"92","author":"Kreisberg","year":"1980","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD008558.pub2-BIB0235|cit235","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0236|cit236","unstructured":"Lily M Godwin M Treating prediabetes with metformin: systematic review and meta-analysis Canadian Family Physician 2009 363 9"},{"issue":"2","key":"10.1002\/14651858.CD008558.pub2-BIB0237|cit237","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jama.2009.1242","article-title":"Comparison of registered and published primary outcomes in randomized controlled trials","volume":"302","author":"Mathieu","year":"2009","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0240|cit240","first-page":"CD005061","article-title":"Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus","volume":"12","author":"Moelands","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.amepre.2018.04.038","article-title":"Review of metformin use for type 2 diabetes prevention","volume":"55","author":"Moin","year":"2018","journal-title":"American Journal of Preventive Medicine"},{"issue":"7","key":"10.1002\/14651858.CD008558.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00125-013-2902-4","article-title":"Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis","volume":"56","author":"Morris","year":"2013","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2337\/diab.28.12.1039","article-title":"Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance","volume":"28","author":"National Diabetes Data Group","year":"1979","journal-title":"Diabetes"},{"issue":"3","key":"10.1002\/14651858.CD008558.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/dom.13121","article-title":"Different intervention strategies for preventing type 2 diabetes mellitus in China: A systematic review and network meta-analysis of randomized controlled trials","volume":"20","author":"Pang","year":"2018","journal-title":"Diabetes Obesity Metabolism"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD008558.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.amjmed.2007.09.016","article-title":"Meta-analysis: metformin treatment in persons at risk for diabetes mellitus","volume":"121","author":"Salpeter","year":"2008","journal-title":"American Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0247|cit247","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002967.pub4","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","author":"Salpeter","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"23","key":"10.1002\/14651858.CD008558.pub2-BIB0248|cit248","first-page":"1604","article-title":"Treatment of metformin-associated lactate acidosis by haemodialysis","volume":"174","author":"Schousboe","year":"2012","journal-title":"Ugeskrift for Laeger"},{"issue":"5","key":"10.1002\/14651858.CD008558.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"303","DOI":"10.7326\/0003-4819-154-5-201103010-00004","article-title":"Racial differences in glycemic markers: a cross-sectional analysis of community-based data","volume":"154","author":"Selvin","year":"2011","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0251|cit251","unstructured":"Sterne JA Egger M Moher D Boutron I (editors) Chapter 10: Addressing reporting biases. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"9131","key":"10.1002\/14651858.CD008558.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD008558.pub2-BIB0253|cit253","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005061.pub2","article-title":"Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose","author":"Laar","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/epirev\/mxr002","article-title":"Predisease: when does it make sense?","volume":"33","author":"Viera","year":"2011","journal-title":"Epidemiologic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008558.pub2-BIB0255|cit255","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000009.pub4","article-title":"Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate","author":"Vist","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its compliactions. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0257|cit257","first-page":"1","article-title":"Part 1: diagnosis and classification of diabetes mellitus","volume-title":"Report of a World Health Organization Consultation","author":"diagnosis","year":"1999"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0258|cit258","unstructured":"World Health Organization\/ International Diabetes Federation Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO\/IDF consultation http:\/\/www.idf.org\/webdata\/docs\/WHO_IDF_definition_diagnosis_of_diabetes.pdf 2006"},{"issue":"8","key":"10.1002\/14651858.CD008558.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1172\/JCI14178","article-title":"The blooming of the French lilac","volume":"108","author":"Witters","year":"2001","journal-title":"Journal of Clinical Investigation"},{"issue":"7644","key":"10.1002\/14651858.CD008558.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008558.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"g4485","DOI":"10.1136\/bmj.g4485","article-title":"The epidemic of pre-diabetes: the medicine and the politics","volume":"349","author":"Yudkin","year":"2014","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD008558.pub2-BIB0262|cit262","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008558","article-title":"Metformin for people with impaired glucose tolerance or impaired fasting blood glucose","author":"L\u00fc","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD008558.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T16:14:18Z","timestamp":1695485658000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008558.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Metabolic and Endocrine Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,12,3]]},"references-count":262,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008558.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,3]]}}}